SAB Biotherapeutics, Inc. (SABS) vs X4 Pharmaceuticals, Inc. (XFOR)
SAB Biotherapeutics, Inc. and X4 Pharmaceuticals, Inc. are both Biotechnology companies. SAB Biotherapeutics, Inc. and X4 Pharmaceuticals, Inc. are of similar size ($304.8M and $297.4M). X4 Pharmaceuticals, Inc. grew revenue faster over the last twelve months: −51.7% against −60.3%. SAB Biotherapeutics, Inc. has the higher net margin (0.00% vs −568.8%) and the higher return on invested capital (−39.0% vs −226.6%). Across the 18 metrics below, SAB Biotherapeutics, Inc. leads on 12 and X4 Pharmaceuticals, Inc. on 6.
Valuation
Profitability
| Metric | SABS | XFOR | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 81.51% | 65.16% |
| Operating margin | 0.00% | (554.71%) | 0.00% |
| Net margin | 0.00% | (568.80%) | 0.00% |
| Free cash flow margin | 0.00% | (559.95%) | 0.00% |
| Return on equity | (19.21%) | (113.08%) | (57.72%) |
| Return on assets | (16.24%) | (50.32%) | (49.22%) |
| Return on invested capital | (38.97%) | (226.62%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack